-- Conference Call Scheduled for 4:30 p.m. ET –
SAN
DIEGO, April 25, 2022 /PRNewswire/ -- Evofem
Biosciences, Inc., (Nasdaq: EVFM) will hold a webcast and
conference call to discuss financial results and business
highlights for the first quarter ended March 31, 2022 as
follows:
Date:
|
Wednesday, May 4,
2022
|
|
|
Time:
|
4:30 p.m. ET (1:30 p.m.
PT)
|
|
|
Live call:
|
(877) 407-0890 (U.S.
toll-free) or
(201)
389-0918
|
|
|
Webcast (live and
archived) and
related slide presentation:
|
https://evofem.investorroom.com/2022Q1Results
or
https://www.webcast-eqs.com/evofem20220504/en
|
|
|
Please connect to the webcast at least 15 minutes prior to the
start of the call to download any software that may be required. If
participating by phone, please dial in approximately 15 minutes
prior to the start of the call using
About Evofem Biosciences
Evofem Biosciences,
Inc., (Nasdaq: EVFM) is developing
and commercializing innovative products to address unmet needs in
women's sexual and reproductive health, including hormone-free,
woman-controlled contraception and protection from certain sexually
transmitted infections (chlamydia and gonorrhea). The
Company's first FDA-approved
product, Phexxi® (lactic acid, citric acid
and potassium bitartrate), is a hormone-free,
on-demand prescription contraceptive vaginal gel. It comes in a box
of 12 pre-filled applicators and is applied 0-60 minutes before
each act of sex. Learn more at
phexxi.com and evofem.com.
Phexxi® is a registered trademark of Evofem
Biosciences, Inc.
Investor Relations Contact
Amy
Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
Mobile: (917) 673-5775
Media Contact
Jack Hirschfield
Evofem Biosciences
jhirschfield@evofem.com
Mobile: (512) 674-5163
View original content to download
multimedia:https://www.prnewswire.com/news-releases/evofem-biosciences-to-report-first-quarter-2022-results-and-provide-corporate-update-on-wednesday-may-4-2022-301531647.html
SOURCE Evofem Biosciences, Inc.